Alnylam Joins Max Planck in Suit Against Whitehead, UMass, MIT Over Tuschl IP Portfolio
July 09, 2009
Alnylam Joins Max Planck in Suit Against Whitehead, UMass, MIT Over Tuschl IP Portfolio
The lawsuit alleges that the defendants have sought to include in their patent applications inventions that belong solely to Max Planck and licensed exclusively to Alnylam. While licenses to the IP have been a big moneymaker for Alnylam, some companies have begun looking to alternative RNAi technologies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam, Max Planck Say Tuschl-I Patent Issuance Imminent, Ask for Court Order
July 16, 2009 / Gene Silencing News - University of Utah Aims to Keep RNAi IP Suit Against UMass Officials on Track
May 17, 2012 / Gene Silencing News - Key RNAi Players Named in Witness Lists in Tuschl IP Dispute
January 14, 2010 / Gene Silencing News - In Ongoing Tuschl IP Row, USPTO OKs Planck’s Request to Pull Power of Attorney from Whitehead
September 17, 2009 / Gene Silencing News - Defendants in Tuschl-I IP Suit Cast Doubt on Claims of Pending Patent Issuance
July 16, 2009 / Gene Silencing News